Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All Patients over age 18 undergoing non-emergent repair of type I-III TAA~Exclusion Criteria:~* Pregnancy~* Patients with hepatic impairment (increase of ALT or AST three times normal)~* Patient taking clonidine or tricyclic antidepressants.~* Patients taking opioids or benzodiazepines chronically (\> 2 doses a day for \> 1 month)~* Patients with second or third degree heart block without a pacer~* Patients undergoing emergency repair of TAA~* Intraoperative cardiac arrest~* Intraoperative massive blood loss (\>10 l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Normal Saline
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).